Key result
Intravenous administration of NIP-142 (3 mg/kg) terminated vagally induced atrial fibrillation in 5 of 6 dogs and anatomically induced atrial flutter in all 6 dogs.
Why the study?
Does the novel Class III antiarrhythmic agent NIP-142 terminate and prevent reinitiation of atrial fibrillation and flutter in a canine model?
Population
Canine model with vagally-induced atrial fibrillation and intercaval crush-induced atrial flutter, as well…
Design
Preclinical
Authors
Loading...
May support NIP-142 development for AF; leaves open human translation and safety.
Does the novel Class III antiarrhythmic agent NIP-142 terminate and prevent reinitiation of atrial fibrillation and flutter in a canine model?
The novel Class III antiarrhythmic agent NIP-142 effectively terminates and prevents reinitiation of atrial fibrillation and flutter in canine models by prolonging atrial refractoriness.
Nagasawa et al. (2002) studied Atrial fibrillation and atrial flutter (induced) (n=33). NIP-142 vs. Baseline was evaluated on Termination of vagally induced atrial fibrillation. Intravenous administration of NIP-142 (3 mg/kg) terminated vagally induced atrial fibrillation in 5 of 6 dogs and anatomically induced atrial flutter in all 6 dogs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: